End-stage renal disease and recruitment to randomized trials: Why is it so difficult? Results from a survey among Norwegian nephrologists

Scandinavian Journal of Urology and Nephrology

Volumn 45, Issue 4, 2011, Pages 285-289

  Lægreid, Inger Karin ^a,b   Aasarød, Knut ^a,b   Jordhøy, Marit ^a,c,d  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d INNLANDET HOSPITAL TRUST   (Norway)

Author keywords

Clinical trials; Dialysis; Elderly; Recruitment

Indexed keywords

ADULT; ARTICLE; CAPACITY BUILDING; DIALYSIS; DOCTOR PATIENT RELATION; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MEDICAL DECISION MAKING; NEPHROLOGIST; NORWAY; PATIENT DECISION MAKING; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); WORKLOAD;

AGED; AGED, 80 AND OVER; CULTURE; DATA COLLECTION; HUMANS; KIDNEY FAILURE, CHRONIC; NORWAY; PATIENT PARTICIPATION; PATIENT SELECTION; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; SPECIALIZATION;

EID: 80051711971     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2011.568957     Document Type: Article

References (25)

1. Lovato LC, Hill K, Hertert S, Hunninghake DB, Probstfield JL. Recruitment for controlled clinical trials: literature summary and annotated bibliography. Control Clin Trials 1997;18(4):328-52. (Pubitemid 27337023)
2. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, et al. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess 1999;3(20):1-143.
3. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006;7:9.
4. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, et al. Recruitment to multicentre trials - lessons from UKCTOCS: descriptive study. BMJ 2008;337:a2079.
5. Rendell JM, Merritt RD, Geddes JR. Incentives and disincentives to participation by clinicians in randomised controlled trials. Cochrane Database Syst Rev 2007 (2): MR000021.
6. Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003;21:2268-75. (Pubitemid 46621862)
7. Siminoff LA, Zhang A, Colabianchi N, Sturm CM, Shen Q. Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol 2000;18:1203-11. (Pubitemid 30159837)
8. Townsley CA, Chan K, Pond G, Marquez C, Siu L, Straus S. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer 2006;6:34.
9. Grande GE, Todd CJ. Why are trials in palliative care so difficult? Palliat Med 2000;14:69-74. (Pubitemid 30095231)
10. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005;23:3112-24. (Pubitemid 46224135)
11. Fukui T, Rahman M, Shimbo T, Morita S, Sakamoto J. Recruitment of patients for a clinical trial: factors on the physician side and reasons on the patient side. Intern Med 2006;45:511-4.
12. Hunninghake D D B, Darby C C A, Probstfield J J L. Recruitment experience in clinical trials: literature summary and annotated bibliography. Control Clin Trials 1987;8(4 Suppl):6-30S.
13. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999;52:1143-56. (Pubitemid 29535414)
14. Kramer A, Stel V, Zoccali C, Heaf J, Ansell D, Gronhagen-Riska C, et al. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant 2009: gfp519.
15. Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007;146:177-83. (Pubitemid 351650630)
16. The Norwegian Renal Registry. Annual report; 2008.
17. Strippoli G F M, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 2004;15:411-9. (Pubitemid 38140782)
18. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84. (Pubitemid 44749316)
19. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98. (Pubitemid 44749317)
20. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-9. (Pubitemid 35461657)
21. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADE-MEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13:1307-20. (Pubitemid 34441412)
22. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48. (Pubitemid 41058323)
23. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010;363:609-19.
24. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48(Suppl 1):S2-90.
25. Dombros N, Dratwa M, Feriani M, Gokal R, Heimburger O, Krediet R, et al. European best practice guidelines for peritoneal dialysis. 2 The initiation of dialysis. Nephrol Dial Transplant 2005;20(Suppl 9):ix 3-7.